These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11091778)

  • 41. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme.
    Steffen T; Blättler R; Gutzwiller F; Zwahlen M
    Eur J Public Health; 2001 Dec; 11(4):425-30. PubMed ID: 11766485
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Injecting drug users in Bangladesh: prevalence of syphilis, hepatitis, HIV and HIV subtypes.
    Azim T; Bogaerts J; Yirrell DL; Banerjea AC; Sarker MS; Ahmed G; Amin MM; Rahman AS; Hussain AM
    AIDS; 2002 Jan; 16(1):121-3. PubMed ID: 11741170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Hepatitis B and C among injecting drug users living with HIV in São Paulo, Brazil].
    Marchesini AM; Prá-Baldi ZP; Mesquita F; Bueno R; Buchalla CM
    Rev Saude Publica; 2007 Dec; 41 Suppl 2():57-63. PubMed ID: 18094787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Syphilis among intravenous drug-using population: epidemiological situation in St Petersburg, Russia.
    Karapetyan AF; Sokolovsky YV; Araviyskaya ER; Zvartau EE; Ostrovsky DV; Hagan H
    Int J STD AIDS; 2002 Sep; 13(9):618-23. PubMed ID: 12230926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. UNODC and the National Administration of Penitentiaries launched harm reduction programme in Romanian prisons.
    Iliuta C
    Int J Prison Health; 2009; 5(1):52-3. PubMed ID: 25758930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementation of rapid HIV and HCV testing within harm reduction programmes for people who inject drugs: a pilot study.
    Fernàndez-López L; Folch C; Majó X; Gasulla L; Casabona J
    AIDS Care; 2016; 28(6):712-6. PubMed ID: 27007000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?
    Hope VD; Judd A; Hickman M; Lamagni T; Hunter G; Stimson GV; Jones S; Donovan L; Parry JV; Gill ON
    Am J Public Health; 2001 Jan; 91(1):38-42. PubMed ID: 11189821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are HIV, HBV and HCV Voluntary Counseling and Testing Programs Needed in Balkans?
    Sultana C; Schweitzer AM; Bogdan M; Ruta S
    Balkan Med J; 2018 Mar; 35(2):219-220. PubMed ID: 29553468
    [No Abstract]   [Full Text] [Related]  

  • 49. Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service.
    Craine N; Parry J; O'Toole J; D'Arcy S; Lyons M
    J Viral Hepat; 2009 Mar; 16(3):219-22. PubMed ID: 19175879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis.
    Nordt C; Stohler R
    Lancet; 2006 Jun; 367(9525):1830-4. PubMed ID: 16753485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV liver disease: the Indian scenario.
    Meisheri YV
    Indian J Gastroenterol; 1997 Oct; 16(4):162-3. PubMed ID: 9357201
    [No Abstract]   [Full Text] [Related]  

  • 52. Can we reduce the burden of morbidity in HIV-infected injecting drug users?
    Selwyn PA
    AIDS; 1996 Oct; 10(12):1429-30. PubMed ID: 8902074
    [No Abstract]   [Full Text] [Related]  

  • 53. [HIV: new cases have decreased by 10 %].
    Drompt L
    Rev Med Suisse; 2015 May; 11(476):1214-5. PubMed ID: 26182647
    [No Abstract]   [Full Text] [Related]  

  • 54. Rates of new HIV diagnoses in Switzerland remain high but no longer rising.
    Gebhardt M
    Euro Surveill; 2005 Feb; 10(2):E050217.3. PubMed ID: 16685100
    [No Abstract]   [Full Text] [Related]  

  • 55. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.
    Nolan S; Dias Lima V; Fairbairn N; Kerr T; Montaner J; Grebely J; Wood E
    Addiction; 2014 Dec; 109(12):2053-9. PubMed ID: 25041346
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review.
    Abdul-Quader AS; Feelemyer J; Modi S; Stein ES; Briceno A; Semaan S; Horvath T; Kennedy GE; Des Jarlais DC
    AIDS Behav; 2013 Nov; 17(9):2878-92. PubMed ID: 23975473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study.
    Russmann S; Dowlatshahi EA; Printzen G; Habicht S; Reichen J; Zimmermann H
    BMC Gastroenterol; 2007 Feb; 7():5. PubMed ID: 17280611
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users.
    Wright NM; Tompkins CN
    Harm Reduct J; 2006 Sep; 3():27. PubMed ID: 16956393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland.
    Somaini B; Wang J; Perozo M; Kuhn F; Meili D; Grob P; Flepp M
    AIDS Care; 2000 Aug; 12(4):449-60. PubMed ID: 11091778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.